therapy are well established and the combination regimens including a fl uoropyrimidine + oxaliplatin are the current standard of care. OBJECTIVES: To compare costs of XELOX with FOLFOX-4 as adjuvant treatment for stage III colon cancer under Brazilian private payer perspective. METHODS: Both regimens demonstrated to signifi cantly improve disease-free survival when compared to 5-FU/LV for adjuvant treatment of stage III colon cancer (MOSAIC and XELOXA trials). In the absence of head-to-head trials comparing both regimens, an indirect comparison using Butcher approach (Butcher 1997) was conducted. No difference was found regarding effi cacy of regimens (XELOX vs. FOLFOX-4 in disease-free survival: HR 1.03, 95% CI 0.81, 1.29); therefore, a cost-minimization analysis was used. a modifi ed Delphi panel identifi ed local practices to manage severe adverse events (SAEs) of each scheme. Only direct costs were considered for a patient with 1.7 m 2 . Drug prices were obtained from offi cial public sources (Kairos Magazine, April 2010) and administration costs from medical society physicians fee list (CBHPM2008, v.5). Time horizon was 6 months according to clinical recommendations: eight cycles for XELOX and 12 for FOLFOX-4. Discounting was not applied. RESULTS: XELOX is less costly than FOLFOX-4 ($Brz49,862 vs. $Brz57,846). XELOX has higher acquisition costs which is offset by savings in medical resource utilization. Mean acquisition costs for XELOX were R$4185 higher than with FOLFOX-4, but costs to treat SAEs and administration costs were $Brz12,169 higher for FOLFOX-4. One-way sensitivity analysis confi rmed the robustness of results. CONCLUSIONS: Findings suggest XELOX as a cost-saving therapy for the adjuvant setting under the private payer perspective in Brazil when compared to FOLFOX-4. Recently, the international NO16968 study reported results confi rming the effi cacy of XELOX in this setting, and evidence suggests that both regimens have at least equivalent effi cacy. Therefore, medical and societal resource utilization are important factors for providers, patients, and payers. The objective of this analysis was to compare total costs required to treat an average aCC patient with either XELOX or FOLFOX4 in Switzerland. METHODS: In the absence of a direct comparison, detailed medical resource utilization (MRU) data collected for XELOX from study NO16,968 (aCC) and for FOLFOX4 from study NO16,966 (metastatic colorectal cancer) were analyzed. The FOLFOX4 regimens are identical in both indications; therefore, MRU data from NO16,966 were considered valid proxies. In addition to direct MRU (chemotherapy, hospitalizations due to adverse events [AEs], ambulatory encounters, AE medication, and central venous access [CVA] placements), patient time and travel costs for hospitalizations, ambulatory encounters, and drug administration were estimated. Unit costs were derived from offi cial tariffs (Spezialitätenliste, Tarmed 2010 for drug costs and physician services), offi cial statistics (hospital cost, mean hourly salary) and tax guidelines (travel costs). Total costs while on treatment (24 weeks) for an average patient with aCC were compared. RESULTS: On average, XELOX saved CHF 11,471 per patient versus FOLFOX4. CHF 8883 resulted from savings in direct costs, mainly driven by savings in drug administration (CHF 9312) and CVA placements (CHF 1730). Savings in patient time and travel costs amounted to CHF 2588. CONCLUSIONS: XELOX appears to be cost-saving versus FOLFOX4 in aCC from both a Swiss health-care system and the societal perspective, assuming equivalent effi cacy for the two regimens. Considering the high incidence of colon cancer in Switzerland, substantial overall savings may be realized by routine use of XELOX in this indication.
PCN94 CAPECITABINE + OXALIPLATIN (XELOX) VS. 5-FU/LV + OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC): COMPARISON OF DIRECT MEDICAL AND SOCIETAL (INDIRECT) COSTS
Winterhalder R 1 , Delmore G 2 , van Lier M 3 , Urspruch A 4 , Hieke K 5 1 Luzerner Kantonsspital, Luzern, Switzerland; 2 Kantonsspital Thurgau, Frauenfeld, Switzerland; 3 Roche Pharma (Schweiz), Reinach, Switzerland; 4 F. Hoffmann-La Roche Ltd., Basel, Switzerland; 5 NEOS Health AG, Binningen, Switzerland OBJECTIVES: FOLFOX4 has been the chemotherapy of choice for patients with stage III colon cancer. Recently, the international NO16968 study reported results confi rming the effi cacy of XELOX in this setting, and evidence suggests that both regimens have at least equivalent effi cacy. Therefore, medical and societal resource utilization are important factors for providers, patients, and payers. The objective of this analysis was to compare total costs required to treat an average aCC patient with either XELOX or FOLFOX4 in Switzerland. METHODS: In the absence of a direct comparison, detailed medical resource utilization (MRU) data collected for XELOX from study NO16,968 (aCC) and for FOLFOX4 from study NO16,966 (metastatic colorectal cancer) were analyzed. The FOLFOX4 regimens are identical in both indications; therefore, MRU data from NO16,966 were considered valid proxies. In addition to direct MRU (chemotherapy, hospitalizations due to adverse events [AEs], ambulatory encounters, AE medication, and central venous access [CVA] placements), patient time and travel costs for hospitalizations, ambulatory encounters, and drug administration were estimated. Unit costs were derived from offi cial tariffs (Spezialitätenliste, Tarmed 2010 for drug costs and physician services), offi cial statistics (hospital cost, mean hourly salary) and tax guidelines (travel costs). Total costs while on treatment (24 weeks) for an average patient with aCC were compared. RESULTS: On average, XELOX saved CHF 11,471 per patient versus FOLFOX4. CHF 8883 resulted from savings in direct costs, mainly driven by savings in drug administration (CHF 9312) and CVA placements (CHF 1730). Savings in patient time and travel costs amounted to CHF 2588. CONCLUSIONS: XELOX appears to be cost-saving versus FOLFOX4 in aCC from both a Swiss health-care system and the societal perspective, assuming equivalent effi cacy for the two regimens. Considering the high incidence of colon cancer in Switzerland, substantial overall savings may be realized by routine use of XELOX in this indication.
PCN95 A MARKOV MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF OMACETAXINE IN CHRONIC MYELOID LEUKEMIA
Brereton NJ 1 , Batty AJ 1 , Foy CF 2 , McCormick AL 2 1 BresMed Health Solutions, Sheffi eld, UK; 2 Complete Market Access, Macclesfi eld, UK OBJECTIVES: In patients with chronic myeloid leukemia (CML), fi rst-line treatment with imatinib therapy is benefi cial. In cases of imatinib failure, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Omacetaxine has a novel mode of action and acts independently of TKIs; thus, it may have therapeutic advantages for patients who have developed resistance to TKI therapy and have no available treatment options. The objective was to develop a health economic model to estimate the cost-effectiveness of omacetaxine in the treatment of CML. METHODS: A costutility Markov model was developed to capture the progression of CML and treatment effects. The model was developed from the perspective of the French health-care system. Patients entered the model treated either with omacetaxine or standard care, in one of three phases: chronic, accelerated, or blast phase, having failed on imatinib therapy (through resistance or intolerance). Patients then moved to states of response, no response, or death. Survival estimates for nonresponding and responding patients were taken from studies 202 and 203. These were extrapolated using parametric curve fi ts to estimate survival beyond the end of the trial. Resource use was based on the trial and from the expert opinion of a panel of French clinicians. Unit costs and utilities were elicited from the literature. One-way and probabilistic sensitivity analyses (PSA) were performed. RESULTS: The deterministic results demonstrated that treatment with omacetaxine is cost-effective at a threshold of c30,000. Sensitivity analysis showed that results were most sensitive to cost of omacetaxine, utility score, and survival benefi t. PSA results showed that the model was suffi ciently robust to parameter uncertainty. CONCLUSIONS: The analysis demonstrated that omacetaxine is cost-effective in the treatment of CML patients who are resistant to TKI therapy and have no available treatment options.
PCN96 A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)
McLeod EJ 1 , Lloyd A 1 , Samyshkin Y 1 , Prunièras F 2 , Canney P 3 1 IMS Health, London, UK; 2 ABRAXIS BIOSCIENCE, Paris, France; 3 Beatson West of Scotland Cancer Centre, Glasgow, UK OBJECTIVES: Paclitaxel albumin (P-A, Abraxane®) is nanoparticle albumin-bound paclitaxel formulated without use of irritant solvents that are responsible for many of the hypersensitivity and dose-limiting adverse events (AEs). Previous research has compared its cost-effectiveness to solvent-based paclitaxel (S-P) and docetaxel (DOC) in a cohort of patients with mixed treatment history. This study examined P-A's costeffectiveness for pretreated MBC, the population specifi ed in the European license. METHODS: A Markov model with progression-free, progressed, and mortality states was developed to estimate costs and outcomes over 5 years from a UK NHS perspective. Included from published sources were the costs at 2009 prices of drugs, administration, AEs, and supportive care. Published utility weights were applied to health states to estimate the impact of response, disease progression, and AEs on qualityadjusted life-years (QALYs). Clinical data for pretreated patients receiving P-A 260 mg/m 2 3-weekly (q3w) and S-P 175 mg/m 2 q3w were from Gradishar (2005) . Using Bucher's methods, an indirect comparison with Jones (2005) provided estimates of clinical parameters for DOC 100 mg/m 2 q3w. Weibull extrapolations of survival data generated transition probabilities. RESULTS: Compared to S-P, P-A achieved an extra 0.164 QALYs, 0.263 life-years, and incurred additional costs of £4,137 per patient treated. This translated to an incremental cost-effectiveness ratio of £25,209/ QALY. P-A saved £697 when compared to DOC, with a marginal QALY gain of 0.0037 and no life-expectancy divergence. Probabilistic sensitivity analysis versus DOC indicated a 61% likelihood of P-A satisfying a willingness-to-pay threshold of £30,000/QALY. Both comparisons were sensitive to drug costs and survival estimates. Accounting for potential drug wastage did not infl uence interpretation of results from either comparison. CONCLUSIONS: The model found that P-A gave better outcomes than S-P or DOC and was cost-effective compared to both interventions. This depended upon greater effi cacy than S-P and a more favorable safety profi le than DOC.
PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
McNamara S 1 , Moore L 1 , Ray J 2 1 Roche Products Limited, Welwyn Garden City, Hertfordshire, UK; 2 F. Hoffmann-La Roche Ltd., Basel, Switzerland OBJECTIVES: To assess the cost-effectiveness of trastuzumab/anastrozole compared to lapatinib/letrozole, anastrazole, and letrozole for the treatment of HER2+/HR+ mBC patients in whom treatment with an aromatase inhibitor is suitable from a UK NHS perspective. METHODS: An area under the curve model based on the TAnDEM (trastuzumab/anastrozole vs. anastrozole) and EGF30008 (lapatinib/letrozole vs. letrozole) RCTs and the fi ndings of a mixed treatment comparison (MTC) conducted on endocrine treatments in HR+ mBC was developed in Excel. a rank preserving structural failure time (RPSFT) model was utilized to account for the 70% crossover in TAnDEM. In the base-case, no attempt to account for the sizeable additional imbalance in 2nd line chemotherapy was made. The anastrozole PFS and RPSFT-adjusted OS curves from TAnDEM were utilized as a baseline from which to implement the required indirect comparisons under the assumption of an AI "class effect" (as suggested by expert clinical opinion and confi rmed by the MTC). The present value of all costs and health outcomes attributable to each treatment option were calculated and the effi ciency frontier defi ned. Extensive deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Anastrozole is dominated by letrozole. Lapatinib/letrozole is extendedly dominated by a combination of letrozole monotherapy and trastuzumab/anastrozole. Trastuzumab/ anastrozole produced the most QALYs of all regimens. Trastuzumab/anastrozole and letrozole defi ne the effi ciency frontier with a base-case ICER of £54,336/QALY. The use of the utility values derived from EGF30008 caused this ICER to fall to £44,497/ QALY. CONCLUSIONS: Lapatinib/letrozole is not a cost-effective use of fi nite NHS resources at any cost-effectiveness threshold. As no attempt was made to account for the imbalance of 2nd line chemotherapy in TAnDEM (31% in anastrozole vs. 8% for trastuzumab/anastrozole) and relatively conservative utility values were used within the model the base-case ICER of trastuzumab/anastrozole vs. letrozole (£54,336/ QALY) should be regarded as conservative and the true ICER likely lies below £50,000/QALY gained.
